Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874244 | 1.00 | PDE4A (0.49) | PDE4AALDH1A1 | |
| SCHEMBL18330097 | 1.00 | PDE4A (0.49) | PDE4AALDH1A1 | |
| SCHEMBL30489158 | 0.83 | PDE4A (0.52) | PDE4A | |
| SCHEMBL18330320 | 0.83 | PDE4A (0.52) | PDE4A | |
| SCHEMBL21292082 | 0.82 | PDE4A (0.54) | PDE4A | |
| SCHEMBL29875087 | 0.73 | PDE4A (0.63) | PDE4A | |
| SCHEMBL18330098 | 0.73 | PDE4A (0.63) | PDE4A | |
| SCHEMBL15832437 | 0.70 | PDE4A (0.38) | PDE4AALDH1A1 | |
| SCHEMBL18330100 | 0.69 | PDE4A (0.88) | PDE4A | |
| SCHEMBL30489034 | 0.69 | PDE4A (0.88) | PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766885-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PFIZER INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PDE3B, PDE3A, PDE5A | PDE4A 6/4885ALDH1A1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.